← Back to Search

Tucaresol for HIV

Phase 1

Waitlist Available

Research Sponsored by Aaron Diamond AIDS Research Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patients must be taking certain anti-HIV drugs

Patients must have had plasma viral load less than 50 copies/ml while on their anti-HIV therapy

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial will test the safety of tucaresol in HIV patients also taking HAART, as well as its effect on viral load.

Who is the study for?

This trial is for HIV-positive adults over 18 with undetectable viral loads, more than 300 CD4 T cells/microL, and on successful anti-HIV drugs for at least 6 months without plans to change therapy. Excluded are those with recent vaccinations, hepatitis B/C, tumors, abnormal tests at baseline, pregnancy or breastfeeding status, certain drug use including immune-affecting ones.Check my eligibility

What is being tested?

The study evaluates the safety of tucaresol when added to HAART in HIV-infected patients and its impact on viral load. Participants will continue their current anti-HIV medications while receiving tucaresol to assess any changes in the virus levels within their bodies.See study design

What are the potential side effects?

While specific side effects of tucaresol aren't listed here, common risks may include allergic reactions or interactions with existing medications. Monitoring will occur for any adverse effects related to organ function or overall health.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am currently on anti-HIV medication.

Select...

My HIV viral load is under 50 copies/ml on my current treatment.

Select...

I am 18 years old or older.

Select...

I can attend weekly doctor visits.

Select...

I do not plan to change my HIV treatment during the study.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

0 / 5Eligibility criteria met

Find a Location

Who is running the clinical trial?

Aaron Diamond AIDS Research CenterLead Sponsor

8 Previous Clinical Trials

605 Total Patients Enrolled

Media Library

Treatment Clinical Trial Eligibility Overview. Trial Name: NCT00006209 — Phase 1

Human Immunodeficiency Virus Infection Research Study Groups:

Human Immunodeficiency Virus Infection Clinical Trial 2023: Treatment Highlights & Side Effects. Trial Name: NCT00006209 — Phase 1

Treatment 2023 Treatment Timeline for Medical Study. Trial Name: NCT00006209 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are geriatric patients accepted in this trial?

"This medical trial welcomes adults of any age above 18 years and below 65."

Answered by AI

Are any additional participants being accepted at this time for the clinical trial?

"Per the information on clinicaltrials.gov, this trial is not currently accepting participants. Initially posted in June 2000 and last edited in 2005, it has been inactive for some time; however, there are 484 other medical studies actively enrolling patients presently."

Answered by AI

Is my eligibility sufficient to partake in this endeavor?

"This clinical trial seeks to recruit 24 individuals living with HIV between the ages of 18 and 0. To be eligible, patients must meet the following criteria: being at least 18 years old, having a current positive diagnosis for HIV, possessing more than 300 CD4 T cells per microlitre upon screening, taking specific anti-HIV medications successfully for six months or longer without expectation to change their therapy during the study period, having plasma viral load below 50 copies/ml while on treatment prior to enrolment in this trial as well as undetectable levels throughout all screenings and baseline tests; additionally they need to commit to weekly visits."

Answered by AI